Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fondaparinux Sodium

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Arixtra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Mylan Inc

            Deal Size: $757.2 million Upfront Cash: $310.4 million

            Deal Type: Acquisition September 08, 2020


            Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.